T-cell–based immunotherapy: adoptive cell transfer and checkpoint inhibition

R Houot, LM Schultz, A Marabelle, H Kohrt - Cancer immunology research, 2015 - AACR
R Houot, LM Schultz, A Marabelle, H Kohrt
Cancer immunology research, 2015AACR
Tumor immunotherapy has had demonstrable efficacy in patients with cancer. The most
promising results have been with T-cell–based therapies. These include adoptive cell
transfer of tumor-infiltrating lymphocytes, genetically engineered T cells, and immune
checkpoint inhibitor antibodies. In this review, we describe the different T-cell–based
strategies currently in clinical trials and put their applications, present and future, into
perspective. Cancer Immunol Res; 3 (10); 1115–22.© 2015 AACR.
Abstract
Tumor immunotherapy has had demonstrable efficacy in patients with cancer. The most promising results have been with T-cell–based therapies. These include adoptive cell transfer of tumor-infiltrating lymphocytes, genetically engineered T cells, and immune checkpoint inhibitor antibodies. In this review, we describe the different T-cell–based strategies currently in clinical trials and put their applications, present and future, into perspective. Cancer Immunol Res; 3(10); 1115–22. ©2015 AACR.
AACR